Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.37 |
| ▸ | HTR2B | P41595 | 4/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.36 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14047840 | 0.90 | SIGMAR1 (0.39) | HTR2CHTR2BHTR2ASIGMAR1TNKS2 | |
| SCHEMBL13328795 | 0.85 | SIGMAR1 (0.39) | HTR2CHTR2BHTR2ASIGMAR1TNKS | |
| SCHEMBL13329605 | 0.85 | SIGMAR1 (0.38) | HTR2CHTR2BHTR2ASIGMAR1TNKS | |
| SCHEMBL14047930 | 0.84 | HTR2A (0.42) | HTR2CHTR2BHTR2ASIGMAR1 | |
| SCHEMBL13329595 | 0.82 | SIGMAR1 (0.39) | HTR2CHTR2BHTR2ASIGMAR1TNKS | |
| SCHEMBL14047939 | 0.78 | SIGMAR1 (0.41) | HTR2CHTR2BHTR2ASIGMAR1TNKS2 | |
| SCHEMBL13329638 | 0.77 | HTR2A (0.31) | HTR2AMAPTMEN1KMT2A | |
| SCHEMBL14046797 | 0.77 | MAPT (0.44) | HTR2CHTR2BHTR2AMAPTMEN1 | |
| SCHEMBL13249768 | 0.75 | SIGMAR1 (0.41) | HTR2CHTR2BHTR2ASIGMAR1TNKS2 | |
| SCHEMBL14047934 | 0.75 | HTR2A (0.31) | HTR2AMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318751-B2 | Pyrimidinone derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318751-B2 | Pyrimidinone derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20100113487-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2010-05-06 | — | — | US | disclosed |
| US-20100113487-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2010-05-06 | — | — | US | disclosed |
| WO-2008130584-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113487-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GPR180, GPR17 | HTR2C 721/4885HTR2B 637/4885HTR2A 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.